Mounjaro Injection Dosage
Generic name: tirzepatide 2.5mg in 0.5mL
Dosage form: injection, solution
Drug class: GLP-1 Agonists (Incretin Mimetics)
Medically reviewed by Drugs.com. Last updated on Apr 8, 2025.
Dosage
- The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.
- After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
- If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
- The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.
- If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
- The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
Important Administration Instructions
- Prior to initiation, train patients and caregivers on proper injection technique.
- Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL dose).
- Administer MOUNJARO once weekly, any time of day, with or without meals.
- Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.
- Rotate injection sites with each dose.
- Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.
- When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.
Frequently asked questions
- Mounjaro vs Ozempic: Which is right for you?
- Zepbound Vs Mounjaro: Complete Comparison Guide for Weight Loss and Diabetes Treatment
- Ozempic Side Effects to Watch For
- Why am I not losing weight on Mounjaro?
- How do Ozempic, Mounjaro, Wegovy, Zepbound compare for weight loss?
- Do Ozempic, Wegovy, Mounjaro & Zepbound cause hair loss?
- How long does it take for Mounjaro to start working?
- Mounjaro side effects you need to be aware of
- Can you switch between Ozempic and Mounjaro?
More about Mounjaro (tirzepatide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,339)
- Drug images
- Latest FDA alerts (2)
- Side effects
- During pregnancy
- Support group
- FDA approval history
- Drug class: GLP-1 Agonists (Incretin Mimetics)
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Zepbound
Zepbound (tirzepatide) is an FDA-approved weekly injection for weight loss and obstructive sleep ...
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Lantus
Lantus is a long acting form of insulin used to treat type 1 or type 2 diabetes. Learn about side ...
Tresiba
Tresiba (insulin degludec) is used to treat diabetes mellitus. Includes Tresiba side effects ...
Phentermine
Phentermine is an appetite suppressant used together with diet and exercise to treat obesity. Learn ...
Semaglutide
Semaglutide is a GLP-1 agonist used for weight loss, type 2 diabetes, and reducing cardiovascular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
